Li Zhu Group: The application for market authorization of Lekangchita monoclonal antibody injection has been accepted.

Announcement by LIZHU Group: its holding subsidiary, Zhuhai LIZHU Monoclonal Antibody Biotechnology Co., Ltd., has received the "Acceptance Notice" issued by the National Medical Products Administration for the domestic production drug registration and market approval application of "Leconquitumab Injection", jointly developed by LIZHU Monoclonal Antibody and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd. The drug is intended for adult patients with moderate to severe plaque psoriasis suitable for systemic treatment or phototherapy.